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In diabetes mellitus the risk for the development of athero-sclerosis is enhanced, which results in an increased risk for 
stroke, myocardial infarction, and death.1,2 The exact mecha-
nisms responsible for this accelerated development of ath-
erosclerosis have remained elusive, but excess production of 
reactive oxygen species (ROS) appears to play a major role.3,4 
Many sources of ROS contribute to increased oxidative stress, 
however NADPH oxidases (Nox) and their catalytic subunit 
are the only known enzyme family solely dedicated to pro-
ducing ROS.5,6 Furthermore, Nox isoforms are upregulated in 
the presence of high glucose, making this enzyme family a 
prime candidate for treating diabetes mellitus–related cardio-
vascular disorders.7,8 Several Nox isoforms are present in the 
vasculature, Nox1, Nox2, Nox4, and Nox5. These isoforms 
have been proposed to play an important role in vascular 
pathobiology, inducing both inflammation and fibrosis.6,9–15
Editorial see p 1850 
Clinical Perspective on p 1902
In vascular cells, Nox1 mRNA expression is low under 
physiological conditions but induced in the presence of factors 
elevated in diabetes mellitus, such as platelet derived growth factor 
and angiotensin II (AngII), and other pathological conditions such 
as atherosclerosis and hypertension.16–19 Thus, Nox1 is a potential 
therapeutic target in diabetes mellitus–related vasculopathies. 
Similar roles in vascular disease have been suggested for Nox2, 
Background—In diabetes mellitus, vascular complications such as atherosclerosis are a major cause of death. The key 
underlying pathomechanisms are unclear. However, hyperglycemic oxidative stress derived from NADPH oxidase (Nox), 
the only known dedicated enzyme to generate reactive oxygen species appears to play a role. Here we identify the Nox1 
isoform as playing a key and pharmacologically targetable role in the accelerated development of diabetic atherosclerosis.
Methods and Results—Human aortic endothelial cells exposed to hyperglycemic conditions showed increased expression 
of Nox1, oxidative stress, and proinflammatory markers in a Nox1-siRNA reversible manner. Similarly, the specific Nox 
inhibitor, GKT137831, prevented oxidative stress in response to hyperglycemia in human aortic endothelial cells. To 
examine these observations in vivo, we investigated the role of Nox1 on plaque development in apolipoprotein E–deficient 
mice 10 weeks after induction of diabetes mellitus. Deletion of Nox1, but not Nox4, had a profound antiatherosclerotic 
effect correlating with reduced reactive oxygen species formation, attenuation of chemokine expression, vascular adhesion 
of leukocytes, macrophage infiltration, and reduced expression of proinflammatory and profibrotic markers. Similarly, 
treatment of diabetic apolipoprotein E–deficient mice with GKT137831 attenuated atherosclerosis development.
Conclusions—These studies identify a major pathological role for Nox1 and suggest that Nox1-dependent oxidative stress 
is a promising target for diabetic vasculopathies, including atherosclerosis. (Circulation. 2013;127:1888-1902.)
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Nox4 and Nox5.10,20–23 However, Nox2 plays an important 
role in the innate immune system and appears an inappropriate 
target in diabetes mellitus, a condition associated with increased 
susceptibility to infections. Nox4 in the vasculature plays a role in 
ischemia–reperfusion and angiogenesis.20,21 The role of the more 
recently discovered isoform Nox5 in the vasculature has not been 
clearly determined, and this isoform is not present in the mouse 
or rat.6,24
Delineating the precise role of NADPH oxidases in any 
disease condition and proof-of-principle studies have been 
limited by the lack of specificity of available pharmacological 
inhibitors.5,6,18 GKT137831 now represents the first specific, 
orally and chronically active Nox inhibitor with a relative 
specificity for Nox1 and Nox4.25,26
To delineate the contribution of Nox in promoting ath-
erosclerosis in diabetes mellitus, we began with a human in 
vitro model of diabetes mellitus–associated oxidative stress 
using human aortic endothelial cells (HAEC) cultured under 
high glucose conditions. Production of reactive oxygen spe-
cies as well as proinflammatory and profibrotic markers were 
assessed under high glucose conditions and after siRNA 
silencing as well as after treatment with GKT137831. The in 
vivo relevance of our findings was then examined in genetic 
mouse models of atherosclerosis (apolipoprotein E–deficient 
[ApoE−/−]) 10 weeks after induction of diabetes mellitus with 
streptozotocin in mice with and without deletion of various 
Nox isoforms or GKT137831 treatment. Our findings not only 
clearly identify Nox1 as the key source of ROS in the vascula-
ture in diabetes mellitus but also provide evidence of a patho-
physiologic role for this low-abundance Nox isoform.
Methods
Refer to Methods in the online-only Data Supplement for greater 
detail.
Animal Models
Nox127 and Nox420 knockout mice were backcrossed onto ApoE−/− 
mice (ARC, WA, Australia) for 10 generations to generate double 
knockout animals (Transgenix, USA). Six-week-old Nox4−/−ApoE−/−, 
Nox4+/+ApoE−/−, Nox1−/yApoE−/−, Nox1+/yApoE−/− and ApoE−/− male 
mice were rendered diabetic by 5 daily IP injections of streptozotocin 
(Sigma-Aldrich, St Louis, MO) at a dose of 55 mg/kg.28 A subgroup 
of diabetic and nondiabetic ApoE−/− mice were administered the Nox 
inhibitor, GKT137831 (GKT) by daily gavage at a dose of 60 mg/kg/d 
for 10 weeks. After 10 weeks, animals were anaesthetised by sodium 
pentobarbitone IP (100 mg/kg body weight; Euthatal, Sigma-Aldrich, 
Castle Hill, NSW, Australia) and organs were rapidly dissected.
Nox Inhibition
GKT137831, a member of the pyrazolopyridine dione family, is a 
specific inhibitor of both Nox1 and Nox4.25,26
Atherosclerotic Plaque Area Quantification
Assessment of plaque area was undertaken using en face analysis, af-
ter staining with Sudan IV-Herxheimer’s solution (BDH, Poole UK) 
as previously described.29
Ex Vivo Vessel Chamber Studies
Isolated aortas were removed and mounted in a vessel chamber for 
the measurement of adherence of fluorescently labeled human leuko-
cytes as previously described.30
Quantitative RT-PCR
Total RNA was extracted after homogenising whole aorta (Polytron 
PT-MR2100; Kinematica, Littau/Lucerne, Switzerland) in TRIzol 
reagent (Invitrogen Australia, Mt Waverly, Vic, Australia) as 
previously described.31 Gene expression were analyzed quantitatively 
as previously described.31
Immunohistochemistry
Paraffin sections of aorta were used to stain for nitrotyrosine (Millipore, 
Billercia, MA), F4/80 (Abcam, Cambridge, MA), monocyte chemoat-
tractant protein 1 (MCP-1; BioVision, CA) and 4-Hydroxynonenal 
(4-HNE) (Abcam, Cambridge MA) as previously described.31
Measurement of H2O2 and Superoxide Production 
in Aortic Tissue
Aortic hydrogen peroxide generation was measured by Amplex red 
using a commercial kit (Molecular Probes, Eugene, OR).32 Aortic 
superoxide was measured using high pressure liquid chromatography 
calibrated to measure DHE by a previously established method.33
Cell Culture Experiments
HAECs were obtained from Clonetics (Lonza) and grown in EGM-2 
endothelial growth media at either normal (5 mmol/L) glucose or high 
glucose (25 mmol/L). Cells used for RT-PCR were plated and incu-
bated for 2 days, then supplemented with GKT137831 and incubated 
for 24 hours before being harvested for RNA isolation. Cells that 
were used for ROS measurements were incubated with GKT137831 
for 1 hour before harvest.
siRNA Knockdown of Nox1 and Nox4 In Vitro
The knockdown of Nox1 and Nox4 was performed in HAECs 
using MISSION siRNA expressing lentivirus vectors as described 
previously.34 The knockdown efficiency in the cells was verified by 
RT-PCR and was greater than 90% for Nox1 and 90% for Nox4.
Measurement of ROS In Vitro
ROS production in HAEC (± Glucose) was measured by DCFDA 
(Invitrogen Molecular Probes), L-012 (Wako Chemicals), Amplex 
Red (Molecular Probes), and DHE (dihydroethidium).32,35
Statistical Analysis
Data were analyzed for normality using the Shapiro-Wilk test before 
being analysed either with a 1-way ANOVA or 2-way ANOVA using 
SPSS Statistics version 20 (IBM) with an LSD post hoc test for multiple 
comparison of the means. Effects of drug dose were assessed by 
ANCOVA with repeated measures. P<0.05 was considered significant. 
Results are expressed as mean±SEM, unless otherwise specified.
Results
Human In Vitro Studies
Gene Expression of Nox Isoforms and ROS Generation
HAECs grown in the presence of high glucose (25 mmol/L) 
showed increased gene expression of Nox1, Nox2, Nox4 
and Nox5 (Table I in the online-only Data Supplement). In 
addition, high glucose increased production of ROS when 
assessed by 4 different approaches, L-012 (F=10.9, P<0.01), 
DCFDA (F=16.7, P<0.01), Amplex Red (F=39.7, P<0.01), 
and DHE (F=38.1, P<0.01) quantified by flow cytometry 
when compared with HAECs grown under normal glucose 
conditions (Figure 1). To identify the responsible Nox 
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Figure 1. Glucose-induced increase in cellular reactive oxygen species was attenuated by transfection with siRNA targeted against Nox1 
and by treatment with GKT137831. ROS as assessed by 4 different methods, L-012, DCFDA, Amplex Red, and DHE by FACS analysis in 
HAECs transfected with siRNA specific for Nox1 or Nox4 grown under normal glucose (5 mmol/L) or high glucose (25 mmol/L) conditions 
(A–H) in addition to HAECs grown under normal glucose (5 mmol/L) or high glucose (25 mmol/L) conditions with or without GKT137831 
(GKT) treatment at either 0 μmol/L, 0.1 μmol/L, and 10 μmol/L (I–L). Data are mean±SEM (n=6/group). Groups were analyzed by 
ANOVA with a LSD post hoc test. Data presented in I–L were analyzed using ANCOVA with repeated measures. *P<0.05 compared with 
nontarget normal Glucose, #P<0.05 compared with nontarget high glucose. DCFDA indicates 2’,7’–dichlorofluorescein diacetate;  
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HAECs with Nox1 siRNA resulted in a 95% reduction of 
Nox1 mRNA (Table II in the online-only Data Supplement), 
and this was associated with a significant reduction in all four 
measures for ROS used (Figure 1A–1D). Specifically, siRNA 
to Nox1 reduced ROS, as assessed by 3 different methods, 
in the high but not normal glucose milieu (L-012, F=6.1, 
P<0.025; DCFDA, F=7.5, P<0.01; DHE, F16.6, P<0.001). 
In contrast, transfecting HAECs with siRNA for Nox4 
did not result in significant attenuation of ROS generation 
when assessed by DHE and L-012. However, when ROS 
was measured using Amplex Red and DCFDA there was a 
significant attenuation in ROS production (Figure 1E–1H). 
Transfection of HAECs with either Nox1 or Nox4 did not have 
any effect on the expression of the remaining Nox isoforms 
(Table II in the online-only Data Supplement). Treatment of 
HAECs with the Nox inhibitor GKT137831 (0.1 μmol/L, 
1 μmol/L, or 10 μmol/L) resulted in a reduced production of 
high glucose–induced ROS formation (Figure 1I–1L). Indeed, 
there was a dose-dependent effect of GKT137831 on ROS, as 
assessed by L-012 (F=15.5, P<0.01, Figure 1I), DHE (F=49.1, 
P<0.01, Figure 1J), DCFDA (F=22.0, P<0.01, Figure 1K), 
and Amplex Red (F=11.9, P<0.01, Figure 1L).
Gene Expression of Proinflammatory and Profibrotic 
Markers
To establish whether the role of Nox1 in HAEC ROS gen-
eration correlated with a similar role in inflammation and 
fibrosis, both inflammatory markers (including MCP-1 and 
vascular cellular adhesion molecule-1 [VCAM-1]) as well as 
fibrotic markers (including the connective tissue growth factor 
[CTGF]) and extracellular matrix proteins such as collagen IV 
and fibronectin were tested. Indeed, knockdown of Nox1 in 
HAECs by siRNA resulted in attenuation of the high glucose–
induced enhanced expression of MCP-1, VCAM-1, CTGF, 
collagen IV, and fibronectin (Table 1). In contrast, silencing of 
Nox4 by siRNA did not affect the mRNA levels of proinflam-
matory and profibrotic markers (Table III in the online-only 
Data Supplement).
Treatment of HAECs under high glucose conditions with 
GKT137831 caused a significant reduction in the expression 
of MCP-1, VCAM-1, CTGF, and fibronectin and collagen IV 
when compared with HAECs grown in high glucose alone 
(Table 2).
Together, our in vitro studies suggest that Nox1, but not 
Nox4, is a major source of vascular ROS and critical for induc-
ing inflammation and fibrosis in high glucose conditions.
Mouse In Vivo Studies
To test our in vitro findings in an in vivo setting, we induced 
insulin-deficient diabetes mellitus using STZ in Nox1 knock-
out animals bred onto the ApoE−/− background (>10 gen-
erations) and observed atherosclerotic plaque area as major 
read-out. In addition, diabetic wild-type ApoE−/− mice 
were treated by gavage once a day with the Nox inhibitor 
GKT137831 for 10 weeks at a dose of 60 mg/kg/d after induc-
tion of diabetes mellitus.
Metabolic Parameters
As expected, at the end of the study all diabetic animals had 
lower body weights (Tables 3 and 4), elevated glucose and 
HbA1c levels in comparison with their nondiabetic controls. 
Deletion of Nox1 or Nox4 or pharmacological Nox inhibition 
with GKT137831 did neither have any effect on body weight, 
glycemic control, nor lipid levels in any diabetic mouse groups 
(Tables 3 and 4). Systolic blood pressure was also unchanged 
among all groups. Diabetic animals displayed a significant 
elevation in serum cholesterol, triglyceride, and LDL levels, 
Table 1. RT-PCR Analysis in HAEC Cells Transfected With 
siRNA Specific for Nox1 and Then Grown in the Presence of 
Normal (5 mmol/L) or High Glucose (25 mmol/L) Conditions for 
24 Hours
Normal Glucose  
(5 mmol/L)
High Glucose  
(25 mmol/L)
Nontarget Nox1 siRNA Nontarget Nox1 siRNA
Nox1 1.0±0.30 0.1±0.01* 2.5±0.42* 0.1±0.01*#
VCAM-1 1.0±0.27 0.6±0.15* 4.9±0.66* 1.0±0.34#
MCP-1 1.0±0.27 1.1±0.17 4.7±1.04* 0.7±0.29#
CTGF 1.0±0.32 0.7±0.21 1.8±0.26* 0.6±0.22#
Collagen IV 1.0±0.38 2.4±0.66 4.2±0.17* 1.9±0.72#
Fibronectin 1.0±0.25 1.4±0.28 3.1±0.64* 2.2±0.35#
Data are Mean±SEM (n=6/group). CTGF indicates connective tissue growth 
factor; HAEC, human aortic endothelial cell; MCP-1, monocyte chemoattractant 
protein; Nox, NADPH oxidase; and VCAM-1, vascular cell adhesion molecule.
*P<0.05 compared with Nontarget grown in Normal Glucose, #P<0.05 
compared with Nontarget grown in High Glucose.
Table 2. RT-PCR Analysis in HAEC Cells Grown in the Presence of Normal (5 mmol/L) or High Glucose (25 mmol/L) Conditions With 
and Without GKT137831 (GKT) at a Dose of 1 µmol/L or 10 µmol/L for 24 Hours













VCAM-1 1.0±0.32 1.4±0.17# 1.7±0.24# 8.5±1.17* 2.3±0.37* 2.4±0.47*#
MCP-1 1.0±0.27 1.6±0.43# 1.2±0.43# 5.9±0.74* 2.1±0.37# 1.8±0.35#
CTGF 1.0±0.15 1.9±0.70# 1.9±0.50# 3.6±0.35* 1.1±0.29# 0.8±0.25#
Collagen IV 1.0±0.20 1.0±0.24# 1.3±0.26# 3.5±0.38* 2.1±0.37# 2.3±0.61*#
Fibronectin 1.0±0.33 1.0±0.20 0.9±0.20# 1.7±0.27* 0.6±0.22# 0.6±0.09#
Data are Mean±SEM (n=6/group). CTGF indicates connective tissue growth factor; HAEC, human aortic endothelial cell; MCP-1, monocyte chemoattractant protein; 
and VCAM-1, vascular cell adhesion molecule.
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which were not affected by deletion of Nox1 or Nox4 (Tables 
3 and 4). Similarly, GKT137831-treated diabetic ApoE−/− mice 
had similar body weights, blood pressures, and metabolic data, 
including total cholesterol and LDL levels compared with 
untreated diabetic ApoE−/− mice (Table 4).
Atherosclerotic Plaque Area
Aortic atherosclerotic plaque area was measured in the aortic 
arch as well as thoracic and abdominal parts of the aorta. All 
diabetic animals showed a significant increase in total athero-
sclerotic plaque areas, which was most prominent in the aortic 
arch (Figure 2A, 2C, and 2E and Figure I in the online-only 
Data Supplement). Importantly, deletion of Nox1 attenuated 
the development of plaque formation in the aorta of diabetic 
Nox1−/yApoE−/− mice, both in the total aorta and even more 
pronounced in the aortic arch when compared to diabetic 
Nox1+/yApoE−/− mice (Figure 2A). In accordance, treatment 
of diabetic ApoE−/− mice with GKT137831 fully prevented 
the development of atherosclerotic plaques within the total 
aorta (diabetes mellitus, F=6.6, P<0.01; GKT137831 treat-
ment F=9.2, P<0.01; interaction of GKT137831 and diabetes 
mellitus, F=6.7, P<0.01) and aortic arch in comparison to 
untreated diabetic ApoE−/− mice. Treatment of nondiabetic 
ApoE−/− mice did not result in any change in atherosclerotic 
plaque area when compared with untreated nondiabetic 
ApoE−/− mice (Figure 2E and 2F). In contrast, in diabetic Nox
4−/−ApoE−/− mice, plaque area was unchanged after 10 weeks 
of diabetes mellitus (Figure 2C and 2D), and there was no 
difference in atherosclerotic plaque area within the thoracic or 
abdominal regions across any group (Table IV in the online-
only Data Supplement). Therefore, Nox4 is unlikely to be 
involved in the development of atherosclerosis under diabetic 
conditions, at least in mice. We also induced diabetes melli-
tus in Nox2−/− mice using STZ. However, these mice showed 
increased susceptibility to Gram-negative infections with 
>50% mortality after 10 weeks and 100% mortality at week 
20 of diabetes mellitus unless treated with antibiotics (Fig-
ure II in the online-only Data Supplement). Thus, we consider 
Nox2 as a rather inappropriate target to prevent or treat diabe-
tes mellitus–associated atherosclerosis. Therefore, we did not 
further investigate the role of Nox2.
Table 3. Metabolic and Biological Data for Control and Diabetic Nox1+/yApoE−/−, Nox1−/yApoE−/− Nox4+/+ApoE−/− and Nox4−/−ApoE−/− 
After 10 Weeks
Nox1 Deletion Studies Nox4 Deletion Studies
Nox1+/yApoE−/− Nox1-/yApoE−/− Nox4+/+ApoE−/− Nox4−/−ApoE−/−
Control Diabetic Control Diabetic Control Diabetic Control Diabetic
Body weight, g 27±1.29 21±0.51* 30±0.22 22±0.65* 29±0.30 24±0.52*† 30±0.85 24±0.75*#†
Systolic BP, mm Hg 101±3 105±2 94±3 98±4 100±3 98±3 99±6 106±4
BG, mmol/L 13.0±0.66 20.0±1.82* 10.2±0.50 20.3±1.49* 11.9±0.50 21.1±1.74*† 13.2±0.89 20.4±1.97*†
HbA1c, % 3.9±0.19 13.4±0.78* 4.5±0.31 15.3±0.69* 7.1±0.23 15.7±0.67*† 4.6±0.29 12.1±0.98*†
Cholesterol, mmol/L 9.7±0.53 15.2±1.26* 9.2±0.50 13.4±1.34* 13.0±1.11 15.0±1.79* 10.1±0.95 12.8±1.50*
Triglycerides, mmol/L 2.1±0.84 4.1±1.52 1.4±0.18 4.5±0.69* 2.3±0.94 3.0±0.67*# 2.4±0.28 3.2±0.75
HDL, mmol/L 2.9±0.93 4.4±1.59 2.3±0.31 1.7±0.32 3.4±0.35 2.7±0.42 2.3±0.38 2.3±0.37
LDL, mmol/L 7.5±0.62 11.6±1.25* 6.2±0.47 9.5±0.91* 8.4±0.97 10.9±0.43*# 6.6±0.58 9.0±1.04
Groups were analysed separately, data are mean±SEM (n=10–15/group). BG indicates blood glucose; BP, blood pressure; HbA1c, hemoglobin A1c; HDL, high-density 
lipoprotein; LDL, low-density lipoprotein; Nox, and NADPH oxidase.
P<0.05 * compared with Nox1+/yApoE−/− Control, # compared with Nox1+/yApoE−/− Diabetic and † compared with Nox1-/yApoE−/− Control, * vs Nox4+/+ApoE−/− Control, 
# vs Nox4+/+ApoE−/− Diabetic and † vs Nox4−/−ApoE−/− Control.
Table 4. Metabolic and Biological Data for ApoE−/− Control and Diabetic Treated With or Without GKT137831 (GKT) for 10 Weeks 
(60 mg/kg/d)
ApoE−/− ApoE−/− & GKT137831
Control Diabetic Control Diabetic
Body weight, g 28±1.17 24.8±0.77* 28.2±0.42 24.8±0.40*†
Systolic BP, mm Hg 102±3 99±3 105±3 107±3
BG, mmol/L 10.4±0.94 21.8±2.11* 13.1±0.50 23.3±1.62*
HbA1c, % 4.5±0.47 11.4±0.88* 4.9±0.78 10.8±0.90*†
Cholesterol, mmol/L 6.7±0.53 12.3±1.05* 7.7±0.41 10.5±0.80*†
Triglycerides, mmol/L 0.8±0.07 1.7±0.39* 0.8±0.14 1.0±0.18#
HDL, mmol/L 1.6±0.11 2.4±0.14* 1.7±0.17 1.7±0.25#
LDL, mmol/L 4.7±0.45 9.0±0.70* 5.9±0.43 7.4±0.61*†
Data are Mean±SEM (n=10–15/group), BG indicates blood glucose; BP, blood pressure; HbA1c, hemoglobin A1c; HDL, high-density lipoprotein; and LDL, low-density 
lipoprotein.
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These results supported the in vitro findings in HAECs and 
translated to a mouse experimental in vivo and pharmacologi-
cal proof-of-principle setting by suggesting that Nox1, but not 
Nox4, is a major player in diabetes mellitus–induced vascular 
pathologies and pharmacologically targetable.
Aortic ROS (Superoxide and H2O2) Production
Only superoxide production (as assessed by DHE staining 




 (as assessed using 
Amplex Red) was significantly increased in the diabetic 
ApoE−/− groups compared with nondiabetic ApoE−/− mice 
(Figure 3A–3F). Further supporting a role of Nox1, we 
observed a significant reduction in superoxide production in 
the aortas from diabetic but not control Nox1-/yApoE−/− animals 
when compared with control and diabetic Nox1+/yApoE−/− mice 
(Figure 3A, F=6.7, P<0.01). The production of superoxide 
was significantly attenuated in diabetic ApoE−/− treated with 
GKT137831 compared with untreated diabetic ApoE−/− 
animals (Figure 3E). Administration of GKT137831 to both 





 levels when compared with untreated control 
and diabetic ApoE−/− mice (Figure 3F). Furthermore, in 
contrast to diabetic Nox1−/yApoE−/− mice, diabetic Nox4 





 production within the aorta (Figure 3C). These data 




 is the 
key form of ROS triggering diabetic atherosclerosis.
Aortic Nitrative and Oxidative Stress
ROS can interact with either NO and nitrite to cause nitra-
tive stress or lipids to cause peroxidation and oxidative 
stress, which can be measured by nitrotyrosine (NT) stain-
ing and 4-HNE, respectively. In the aortic wall, both NT and 
4-HNE were increased in all diabetic animals when com-
pared with vessels from nondiabetic control mice (Figures 
4 and 5). Again, deletion of Nox1 resulted in a significant 
attenuation in NT and 4-HNE staining in the aorta of diabetic 
Nox1−/yApoE−/− mice in comparison with diabetic Nox1+/y 
ApoE−/− mice. Similarly, diabetic ApoE−/− mice treated with 
GKT137831 displayed a significant reduction in NT stain-
ing when compared with the untreated diabetic ApoE−/− mice 
(Figure 4). GKT137831 treatment also resulted in reduced 
Figure 2. Deletion of Nox1 and treatment 
of ApoE−/− mice with GKT137831 reduced 
the development of atherosclerosis 
in diabetes mellitus. Atherosclerotic 
plaque area measured at 10 weeks after 
induction of diabetes mellitus within  
the aortic arch (A, C, and E) and total 
aorta (B, D, and F) for control (Cont)  
and diabetic (Diab) Nox1+/yApoE−/−,  
Nox1–/yApoE−/− mice, and control and 
diabetic Nox4+/+ApoE−/−, Nox4−/−ApoE−/− 
mice. In addition, plaque area was 
measured in control (Cont) and diabetic 
(Diab) ApoE−/− mice treated with or 
without GKT137831 (GKT) for 10 wks (60 
mg/kg/d). Data are mean±SEM (n=8–10/
group). Groups were analyzed separately 
using ANOVA with a LSD post hoc test. 
P<0.05 *compared with Nox1+/y 
ApoE−/− or ApoE−/− Control, #compared 
with Nox1+/yApoE−/− or ApoE−/− Diabetic, 
* vs Nox4+/+ApoE−/− Control, # vs 
Nox4+/+ApoE−/− Diabetic and † vs  
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4-HNE staining in diabetic ApoE−/− but not control ApoE−/− 
mice (Figure 5, F=11.3, P<0.01).
In line with our previous results, deletion of Nox4 neither 
altered NT nor 4-HNE staining in aortas of diabetic ApoE−/− 
mice when compared with diabetic Nox4+/+ApoE−/− mice 
(Figures 4 and 5).
Macrophage Infiltration
Macrophage infiltration, a hallmark of atherosclerosis, was 
assessed by F4/80 immunohistochemistry within whole aor-
tas. It was significantly increased in all diabetic mice com-
pared with aortic vessels from nondiabetic control mice 
(Figure 6). Deletion of Nox1 resulted in a significant reduc-
tion in F4/80 staining in the aorta of diabetic but not control 
Nox1−/yApoE−/− mice in comparison with control and diabetic 
Nox1+/yApoE−/− mice (Figure 6A, F=8.2, P<0.01). Similarly, 
diabetic ApoE−/− mice treated with GKT137831 demon-
strated reduced F4/80 staining in comparison with untreated 
diabetic ApoE−/− mice (Figure 6C). Again, deletion of Nox4 
did not result in a significant reduction in staining for F4/80 
in diabetic Nox4−/−ApoE−/− mice in comparison with diabetic 
Nox4+/+ApoE−/− mice (Figure 6B).
Aortic Vascular Adhesion
Adhesion of leukocytes to the endothelial cell layer is a key step 
in the initiation of atherosclerosis.36 Examination of leukocyte 
adhesion to the aorta using vessel chamber experiments over 
a period of 10 minutes demonstrated a significant increase in 
the number of leukocytes that adhered to the aortic wall of 
diabetic ApoE−/− mice in comparison to nondiabetic ApoE−/− 
mice (Figure 7A and 7B). Deletion of Nox1 significantly 
reduced the number of leukocytes attached to the aortic wall 
compared with diabetic ApoE−/− mice. Similarly treatment of 
diabetic ApoE−/− mice with GKT137831 significantly reduced 
the number of adherent leukocytes (Figure 7A and 7B). 
Deletion of the Nox4 isoform did not result in attenuation of 
the number of leukocytes adhering to the aortic wall (Figure 
7A and 7B).
Vascular Adhesion Markers and Inflammation
Because inflammation and adhesion of monocytes to the vas-
cular wall are critical steps in the initiation and development 
of diabetic atherosclerosis, we examined vascular expression 
of MCP-1 and VCAM-1.
There was a significant increase in the gene expression of 
MCP-1 in the aorta of diabetic animals (Figure 7C–7E). This 
Figure 3. Diabetes mellitus–induced 
elevation in superoxide production is 
ameliorated by deletion of Nox1 and 
treatment of ApoE−/− with GKT137831. 
Whole aorta superoxide production 
measured by DHE/HPLC (A, C, and 
E) and H2O2 (B, D, and F) released 
measured by Amplex red in aortas 
from control (Cont) and diabetic (Diab) 
Nox1+/yApoE−/−, Nox1−/yApoE−/− (A and 
B) in addition to control and diabetic 
Nox4+/+ApoE−/− and Nox4−/−ApoE−/−  
(C and D) mice after 10 wks. 
Furthermore, superoxide and hydrogen 
peroxide were measured in control 
and diabetic ApoE−/− mice treated with 
or without GKT137831 (GKT, 60 mg/
kg/d) after 10 weeks (E and F). Data are 
mean±SEM (n=6/group). Groups were 
analyzed separately using ANOVA with 
a LSD post hoc test, P<0.05 *compared 
with Nox1+/yApoE−/− or ApoE−/− Control, 
#compared with Nox1+/yApoE−/− or  
ApoE−/− Diabetic, * vs Nox4+/+ApoE−/− 
Control, # vs Nox4+/+ApoE−/− Diabetic  
and † vs Nox4−/−ApoE−/− Control.  
DHE indicates dihydroethidium; 
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diabetes mellitus–induced increase was again attenuated in the 
diabetic but not control Nox1−/yApoE−/− (F=9.9, P<0.01) and in 
the GKT137831-treated diabetic ApoE−/− mice (Figure 7C and 
7E), however there was no change in MCP-1 gene expression in 
diabetic Nox4−/−ApoE−/− mice compared with Nox4+/+ApoE−/− 
diabetic mice (Figure 7D). Immunohistochemistry confirmed 
the diabetes mellitus–induced upregulation of MCP-1 protein 
expression in the aortas of diabetic mice, which was signifi-
cantly attenuated by deletion of Nox1 (F=14.1, P<0.01) but 
not Nox4 (Figure 7F–7H). Similarly, treatment of diabetic 
ApoE−/− mice with GKT137831 resulted in reduced MCP-1 
staining (Figure 7H).
As expected, diabetes mellitus was associated with a sig-
nificant increase in the gene expression of aortic VCAM-1, 
which was attenuated in Nox1-/yApoE−/− and GKT137831 
treated diabetic ApoE−/− mice but not in Nox4−/−ApoE−/− mice 
(Figure 8A–8C).
Fibrosis is also a potent feature of diabetes mellitus–
associated atherosclerosis.37 Accordingly, the profibrotic 
growth factor, CTGF, as well as the matrix proteins, fibronectin 
and collagen IV, were significantly upregulated at the mRNA 
level in the aortas of all diabetic mice (Figure 8A–8C). Deletion 
of Nox1 in diabetic Nox1−/yApoE−/− animals, and treatment of 
diabetic ApoE−/− diabetic animals with GKT137831 resulted 
in significantly attenuated gene expression of fibronectin 
and CTGF (Figure 8A and 8C). However, in accordance 
with our other findings, deletion of Nox4 in diabetic Nox4−/− 
ApoE−/− animals did not result in reduced expression of CTGF 
and fibronectin (Figure 8B). With respect to collagen IV 
mRNA levels, Nox1 deletion and GKT137831 reduced gene 
expression in the diabetic but not control mice (Nox1 deletion, 
F=17.0, P<0.01; GKT137831 treatment, F=11.2, P<0.01) but 
there was no effect of Nox4 gene deletion (Figure 8A–8C).
Discussion
This series of experiments provides strong evidence of a major 
pathophysiological role for Nox1, but not Nox4, in advanced 
atherosclerosis in diabetes mellitus. By using both genetic 
and pharmacological approaches, we have demonstrated that 
Figure 4. Nox1 deletion and 
GKT137831 treatment 
attenuates diabetes mellitus–





quantification in the aorta of 
control (Cont) and diabetic 
(Diab) Nox1+/yApoE−/−, 
Nox1-/yApoE−/− (A) and control 
and diabetic Nox4+/+ApoE−/− 
and Nox4−/−ApoE−/− (B) mice. In 
addition, nitrotyrosine was 
measured in control (Cont) and 
diabetic (Diab) ApoE−/− mice (C) 
treated with or without 
GKT137831 (GKT) for 10 wks 
(60 mg/kg/d). Data are 
mean±SEM (n=8–10/group). 
Groups were analyzed separately 
using ANOVA with a LSD post 
hoc test, P<0.05 *compared with 
Nox1+/yApoE−/− or ApoE−/− 
Control, #compared with  
Nox1+/yApoE−/− or ApoE−/−  
Diabetic, * vs Nox4+/+ApoE−/− 
Control, # vs Nox4+/+ApoE−/− 
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in the setting of diabetes mellitus, Nox1 mediates oxidative 
stress, inflammation, and fibrosis and determines plaque size. 
Our studies provide novel mechanistic data demonstrating that 
Nox1 inhibition attenuates diabetes mellitus–induced adhesion 
of inflammatory cells to the vascular wall, a key initiating step 
in the development of atherosclerosis.36 In this study 2 major 
vascular isoforms of the enzyme NADPH oxidase, Nox1 and 
Nox4, were assessed using Nox isoform KO on the atheroscle-
rosis prone ApoE−/− background in the absence and presence 
of the proatherosclerotic stimulus, insulin-deficient diabetes 
mellitus. In vitro, using human endothelial cells, silencing 
of Nox1 using an siRNA approach attenuated high glucose–
induced ROS production and expression of proinflammatory 
cytokines and profibrotic growth factors. Furthermore, the 
novel Nox inhibitor GKT137831 attenuated superoxide pro-
duction, inflammation, and vascular adhesion as well as fibro-
genesis in vitro and in vivo. This pharmacological strategy 
provides a potentially new clinical approach to reduce oxida-
tive stress in the diabetic setting ultimately leading to a dimin-
ished cardiovascular burden as a result of atherosclerosis.
Cardiovascular disease is the major cause for mortality 
and morbidity in diabetic patients.1,2 It has been shown that 
atherosclerosis in diabetes mellitus exhibits characteristic 
features including a more pronounced inflammatory phenotype 
characterized by enhanced vascular macrophage infiltration, 
upregulation of proinflammatory cytokines, and adhesion 
molecules, leading to accelerated adhesion of leucocytes to 
the vascular wall.36,37
Figure 5. Aortic lipid 
peroxidation (4-Hydroxynoneal) 
is reduced in diabetic 
Nox1−/yApoE−/− and diabetic 




quantification in aortas of 
control (Cont) and diabetic 
(Diab) Nox1+/yApoE−/−, 
Nox1−/yApoE−/− (A) and control 
and diabetic Nox4+/+ApoE−/− 
and Nox4−/−ApoE−/− (B) mice. 
In addition, 4-Hydroxynoneal 
was measured in control (Cont) 
and diabetic (Diab) ApoE−/− 
mice (C) treated with or without 
GKT137831 (GKT) for 10 wks (60 
mg/kg/d). Data are mean±SEM 
(n=8–10/group). Groups were 
analyzed separately using 
ANOVA with a LSD post hoc 
test, P<0.05 *compared with 
Nox1+/yApoE−/− or ApoE−/− 
Control, #compared with 
Nox1+/yApoE−/− or 
ApoE−/− Diabetic, * vs 
Nox4+/+ApoE−/− Control, # vs 
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To directly compare the role of Nox1 and Nox4 in a 
model of advanced atherosclerosis in the context of diabetes 
mellitus, we generated double knockout mice by crossing 
Nox1−/y and Nox4−/− with ApoE−/− mice. Only Nox1 deletion 
in ApoE−/− mice prevented the accelerated development of 
atherosclerosis after 10 weeks of diabetes mellitus, whereas 
deletion of Nox4 in diabetic ApoE−/− mice did not protect 
mice from plaque development. This antiatherosclerotic 
effect of Nox1 deletion observed in diabetic Nox1−/
yApoE−/− mice was associated with reduced generation of 
ROS. Activation of inflammatory and fibrotic markers are 
critical processes in the development of diabetes mellitus–
related atherosclerosis.38–41 Consistent with a link between 
Nox1 and the atherosclerotic process, Nox1 deletion was 
associated with attenuation of diabetes mellitus–induced 
vascular macrophage infiltration, expression of adhesion 
molecules and chemokines as well as fibrogenesis. To 
complement these in vivo findings demonstrating a role for 
Nox1 in diabetes mellitus–associated atherosclerosis and 
in the regulation of diabetes mellitus–induced upregulation 
of adhesion molecules, we assessed ex vivo dynamic 
adhesion which was enhanced in the diabetic milieu. Indeed, 
Nox1 but not Nox4 deletion led to attenuation of diabetes 
mellitus–associated enhanced vascular adhesion. Therefore, 
our studies suggest that Nox1 is the most important Nox 
isoform and source of ROS for the development of diabetes 
mellitus–accelerated atherosclerosis and as such a promising 
therapeutic target.
Within the vasculature, Nox1 expression is low under nor-
mal conditions but is increased under pathological conditions 
such as hypertension,11,18,27,42 implicating Nox1 as a potential 
drug target for vasculoprotection. Recent studies have sug-
gested, albeit not investigated in the diabetic context, that 
Nox1 plays a role in vascular smooth muscle cell migration, 
proliferation, and extracellular matrix formation and has been 
implicated in neointima formation,.43 Indeed, Nox1 has been 
Figure 6. Reduced diabetes 
mellitus–induced aortic 
macrophage infiltration in 
diabetic Nox1−/yApoE−/− and 
diabetic GKT137831 ApoE−/− 
treated mice. Macrophage 
infiltration (F4/80) as assessed 
by immunohistochemistry; 
photomicrographs and 
quantification in the aorta of 
control (Cont) and diabetic 
(Diab) Nox1+/yApoE−/−, Nox1-/y 
ApoE−/− (A) and control and 
diabetic Nox4+/+ApoE−/− and 
Nox4−/−ApoE−/− (B) mice. 
Furthermore, macrophage 
infiltration was assessed in 
control (Cont) and diabetic 
(Diab) ApoE−/− mice (C) treated 
with or without GKT137831 
(GKT) for 10 wks (60 mg/kg/d). 
Data are mean±SEM with n=8 
to 10 per group. Groups were 
analyzed separately using 
ANOVA with a LSD post hoc 
test, P<0.05 *compared with 
Nox1+/yApoE−/− or ApoE−/− 
Control, #compared with Nox1+/y 
ApoE−/− or ApoE−/− Diabetic,  
* vs Nox4+/+ApoE−/− Control,  
# vs Nox4+/+ApoE−/− Diabetic  
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implicated in a range of processes related to vascular disease, 
although these studies have focused on earlier events such as 
endothelial dysfunction44 or factors that predispose to athero-
sclerosis such as hypertension or increases in the potent vaso-
constrictor AngII.45 For example, Nox1 has been shown to be 
upregulated by AngII in SHR.45 In the balloon injury model 
in rats a recent report has described a role for Nox1 involv-
ing the direct binding of this enzyme to the AT1 receptor.46 
In STZ-diabetes mellitus, activation of Nox1 but not Nox4 or 
Nox2 has been implicated in eNOS uncoupling and endothe-
lial dysfunction, although these studies were performed in a 
nonatherosclerosis prone mouse model.44
The role of Nox1 in atherosclerosis has not been extensively 
explored. However, studies by Sheehan et al47 have suggested 
that Nox1 plays a role in a different model of atherosclerosis 
using high-fat feeding and in neointima formation. There 
are several differences between our studies and the findings 
by Sheehan et al. First, all our studies were performed in a 
Figure 7. Reduced diabetes 
mellitus–induced aortic 
adhesion of leukocytes and 
monocyte chemoattractant 
protein 1 expression in Nox1-/y 
ApoE−/− and GKT137831-treated 
diabetic ApoE−/− mice. Aortic 
leukocyte adhesion (A and B) in 
addition to monocyte chemo-
attractant protein 1 (MCP-1) 
immunohistochemistry 
quantification and gene 
expression as assessed by 
RT-PCR in the aortas of control 
(Cont) and diabetic (Diab) Nox1+/y 
ApoE−/−, Nox1−/yApoE−/− (C, F) 
and control and diabetic Nox4+/+ 
ApoE−/− and Nox4−/−ApoE−/−  
(D, G) mice. Furthermore, MCP-1 
gene and protein were 
measured in the aorta of control 
(Cont) and diabetic (Diab) 
ApoE−/− mice (E, H) treated with 
or without GKT137831 (GKT) for 
10 wks (60 mg/kg/d). Data are 
mean±SEM (n=8–10/group). 
Groups were analyzed 
separately using ANOVA with a 
LSD post hoc test, P<0.05 
*compared with Nox1+/yApoE−/− 
or ApoE−/− Control, #compared 
with Nox1+/yApoE−/− or ApoE−/−  
Diabetic, * vs Nox4+/+ApoE−/− 
Control, # vs Nox4+/+ApoE−/− 
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hyperglycemic milieu where atherosclerosis is considered to 
be accelerated as a result of interactions between metabolic 
and hemodynamic factors, including upregulation of the local 
vascular renin–angiotensin system in the vasculature.37 In our 
studies we have used the STZ-induced diabetic ApoE−/− mouse, 
a model considered to be the most appropriate model to study 
advanced atherosclerosis in the context of diabetes mellitus.28 
In contrast to our model, which explored a more advanced 
clinically relevant model of atherosclerosis, the study 
by Sheehan et al demonstrated rather modest plaque 
development with much less pronounced effects of Nox1 
deficiency on atherosclerosis.47 Furthermore, the role of 
Figure 8. Amelioration of diabetes mellitus–induced aortic expression of proinflammatory and profibrotic markers in diabetic Nox1−/yApoE−/− 
and GKT137831-treated diabetic ApoE−/− mice. RT-PCR analysis for inflammation and fibrosis markers in aortas of control (Cont) and 
diabetic (Diab) Nox1+/yApoE−/−, Nox1−/yApoE−/− (A) and control and diabetic Nox4+/+ApoE−/− and Nox4−/−ApoE−/− (B) mice. Furthermore, gene 
expression was analysed in aortas of control (Cont) and diabetic (Diab) ApoE−/− mice (C) treated with or without GKT137831 (GKT) for 10 
wks (60 mg/kg/d). Data are mean±SEM (n=6–8/group). Groups were analyzed separately using ANOVA with a LSD post hoc test, P<0.05 
*compared with Nox1+/yApoE−/− or ApoE−/− Control, #compared with Nox1+/y ApoE−/− or ApoE−/− Diabetic, * vs Nox4+/+ApoE−/− Control, # vs 
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other Nox isoforms such as Nox4 in atherosclerosis was not 
considered in that study.
To enhance the potential clinical translation of the 
findings, we included a complementary pharmacological 
approach by using the Nox inhibitor GKT137831,25,26 which 
inhibits both Nox1 and Nox4. Treatment with GKT137831 
mimicked the antiatherosclerotic effect of Nox1 deletion. 
This included inhibition of ROS generation and attenuation of 
diabetes mellitus–induced increased adhesion of leucocytes 
to the vascular wall resulting in a reduction in vascular 
macrophage infiltration, inflammation, and fibrosis ultimately 
leading to attenuation of plaque formation. Importantly, this 
agent did not lead to increased susceptibility to infection. 
GKT137831 also inhibits Nox4, and previously it has been 
claimed that Nox4 silencing in microvascular complications, 
specifically diabetic nephropathy, is protective,48 albeit using 
potentially less specific antisense techniques. Although 
Nox4 has been reported to have vascular effects such as 
actions on angiogenesis in hindlimb ischemia, albeit in a 
normoglycemic setting,49 no effects on atherosclerosis per se 
have been previously defined with respect to this particular 
Nox isoform. In this study, no benefit on atherosclerosis was 
observed in Nox4−/− mice, nor did any in vitro or ex vivo 
studies demonstrate any improvement in vascular adhesion 
or reduction in proinflammatory molecules. Thus, our studies 
do not support a vasculoprotective role for Nox4 in diabetes 
mellitus.
GKT137831 does not appear to have significantly inhibited 
Nox2 at the dose used in this study. Indeed, previous detailed 
studies on the effects of GKT137831 on Nox2 and on relevant 
proteins implicated in neutrophil defense have been reported, 
and indeed GKT137831 was shown to not affect Nox2-
dependent events such as innate microbial killing.26
To complement the in vivo studies, a series of in vitro experi-
ments in human endothelial cells were performed, which were 
consistent with the in vivo findings, demonstrating a central 
role for Nox1 in ROS generation and regulation of a range of 
proinflammatory and profibrotic molecules. Similar benefits 
of GKT137831 in suppressing endothelial ROS production 
in a dose-dependent manner and altering expression of key 
molecules such as MCP-1 and VCAM-1 were also observed. 
A modest effect of the siRNA to Nox1 on Nox4 expression 
was observed, although the significance of these findings are 
unclear.
Nox2 is also upregulated in hyperglycemic states, and thus 
a pathological role for this isoform should be considered. 
However, STZ-induced diabetes mellitus in Nox2−/− mice and 
in particular in Nox2−/−ApoE−/− double KO mice was associ-
ated with increased susceptibility to infections resulting in 
almost 100% mortality. This is reminiscent of humans with 
mutations in Nox2 and reduced Nox2 activity who develop 
chronic granulomatous disease (CGD) and are susceptible to 
infections.50,51 This lethality of Nox2 deletion in diabetes mel-
litus–associated atherosclerosis indicates that Nox2 is likely 
to be an inappropriate target in the context of diabetes mel-
litus. In humans, a role for another Nox isoform, Nox5, which 
is not present in rodents has been suggested in the vascular 
system and warrants further investigation in man.12,52
Conclusion
This study has demonstrated a major role for Nox1 derived 
ROS in diabetes mellitus–associated atherosclerosis. Specifi-
cally, genetic deletion of Nox1 in diabetic ApoE−/− mice was 
associated with reduced diabetes mellitus–associated athero-
sclerotic plaque development, and this may be attributable at 
least in part to reduced adhesion of inflammatory cells to the 
vascular wall, a key initiating step in atherosclerosis develop-
ment. The Nox inhibitor GKT137831 mimicked those effects 
both in vivo and in vitro. Thus, our studies indicate a previ-
ously not reported major pathophysiological role for Nox1 in 
atherosclerosis particularly in a diabetic setting. Thus, Nox1 
inhibition represents a novel therapeutic approach in the pre-
vention and treatment of diabetes mellitus–associated vascu-
lar disorders, such as atherosclerosis.
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Diabetic patients have increased risk of cardiovascular complications, including myocardial infarction, stroke, and periph-
eral vascular disease. The underlying mechanisms responsible for this acceleration of cardiovascular disease in diabetes 
mellitus remain unknown. Antioxidants have in general been disappointing for a range of reasons, including dosing prob-
lems, local availability, and pro-oxidant effects. It is now recognized that NADPH oxidase (Nox)–derived reactive oxygen 
species may be an important mediator of vascular disease, particularly in diabetes mellitus. In this series of experiments we 
demonstrate for the first time a key role for Nox1 in the development of diabetes mellitus–accelerated atherosclerosis. The 
genetic deletion of Nox1 but not Nox4 was associated with reduced adhesion of inflammatory cells to the vascular wall, as 
well as leading to less vascular macrophage infiltration and fibrosis. Importantly, from a clinical translational point of view, 
these results were replicated using a pharmacological Nox inhibitor, GKT137381, which is already in clinical development. 
Furthermore, the in vivo data were complemented by in vitro studies using siRNA silencing to knockdown selectively Nox1 
or Nox 4, and we were able to replicate the effects on reactive oxygen species formation, inflammation, and fibrosis as 
observed in vivo. These studies provide the first definitive evidence that Nox1 is a critical target for advanced atherosclero-
sis, particularly in the diabetic context, and that this isoform is pharmacologically targetable, thereby increasing the clinical 
translational potential of these findings.
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